Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · May 09, 2022

Anti–TNF-α vs Tocilizumab for Treating Refractory Uveitic Macular Edema



Additional Info

Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network
Ophthalmology 2022 May 01;129(5)520-529, M Leclercq, A Andrillon, G Maalouf, P Sève, P Bielefeld, J Gueudry, T Sené, T Moulinet, B Rouvière, D Sène, AC Desbois, F Domont, S Touhami, C El Chamieh, P Cacoub, B Bodaghi, L Biard, D Saadoun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading